News
Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback